Stephen M. Stribbling
- Biotechnology top 5%
- Cancer Research and Treatments 9
- Oncology top 10%
- CAR-T cell therapy research 2
- Cancer Cells and Metastasis 2
-
- Cancer, Hypoxia, and Metabolism 6
-
- Glycosylation and Glycoproteins Research 3
- Biochemical and Molecular Research 2
-
- Monoclonal and Polyclonal Antibodies Research 5
-
- Virus-based gene therapy research 7
- Co-authors
- Caroline J. SpringerSimon TazzymanNicola J. BrownClaire E. LewisCarolyn A. StatonRussell HughesAnderson J. RyanJanet L. Martin
- Cited by
- BiotechnologyOncologyCancer Research
- Partner nations
- United KingdomNew ZealandSwitzerland
In The Last Decade
Stephen M. Stribbling
25 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 96
- Biotechnology 169
- Oncology 278
- Cancer Research 150
- Molecular Biology 655
- Radiology, Nuclear Medicine and Imaging 171
Countries citing papers authored by Stephen M. Stribbling
This map shows the geographic impact of Stephen M. Stribbling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen M. Stribbling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen M. Stribbling more than expected).
Fields of papers citing papers by Stephen M. Stribbling
This network shows the impact of papers produced by Stephen M. Stribbling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen M. Stribbling. The network helps show where Stephen M. Stribbling may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Stephen M. Stribbling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 26 | |
| 2 | 2022 | 49 | |
| 3 | 2022 | 10 | |
| 4 | 2020 | 15 | |
| 5 | 2019 | 31 | |
| 6 | 2019 | 10 | |
| 7 | 2018 | 8 | |
| 8 | 2016 | 42 | |
| 9 | 2011 | 3 | |
| 10 | 2009 | 29 | |
| 11 | 2007 | 12 | |
| 12 | 2003 | 11 | |
| 13 | 2003 | 54 | |
| 14 | 2000 | 42 | |
| 15 | Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer. | 1999 | 17 |
| 16 | Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. | 1999 | 54 |
| 17 | 1997 | 57 | |
| 18 | 1997 | 25 | |
| 19 | 1997 | 62 | |
| 20 | 1995 | 17 |
About Stephen M. Stribbling
Stephen M. Stribbling is a scholar working on Biotechnology, Cancer Research and Toxicology, having authored 25 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer Research and Treatments (9 papers), Virus-based gene therapy research (7 papers), Cancer, Hypoxia, and Metabolism (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Glycosylation and Glycoproteins Research (3 papers), CAR-T cell therapy research (2 papers), Biochemical and Molecular Research (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Biotechnology (169 citations), Oncology (278 citations) and Cancer Research (150 citations). Stephen M. Stribbling has collaborated with scholars based in United Kingdom, New Zealand and Switzerland. Frequent co-authors include Caroline J. Springer, Simon Tazzyman, Nicola J. Brown, Claire E. Lewis, Carolyn A. Staton, Russell Hughes, Anderson J. Ryan, Janet L. Martin, Richard H. J. Beǵent and Robert A. Spooner. Their work appears in journals such as Nature Biotechnology, Journal of Cell Science and Nature Protocols.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.